global head of Biogen’s biosimilars unit. “With the increasing numbers of approved biosimilars, we expect increased savings and sustainability for healthcare systems and an increase in ...

Biogen struggled to consistently generate demand over the last ... as well as under-the-radar businesses like Comfort Systems ...

The thrust of the alliance is directed straight at central nervous system (CNS) disorders – Biogen's core therapeutic focus – and the initial objective is to understand how different forms of ...

Biogen secures rights to commercialize zorevunersen outside North America, while Stoke leads global development and retains U.S. rights. Stoke receives $165 million upfront, up to $385 million in ...

X-ELIO, a global leader in the renewable energy sector, and the Net Zero Consortium for Buyers (NZCB) have announced the signing of six virtual power purchase agreements (PPAs) for a combined total ...

Biogen receives exclusive rights to commercialize ... Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...

Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.

Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...